Bayer looking into established drugs strategy
Bayer is looking into future options for the established drugs business, partly because of price pressure in China, the German company’s head of pharmaceuticals said.
Featured Posts
Top 10 Pipelines To Watch: 2019 Annual Report
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Pharma Innovators Special Feature 2018: Focus on innovation
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
First Year After Launch Special Feature 2018: Don’t look back, someone might be gaining
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Two drugmakers to pay in U.S. charity kickback probe
Astellas and Amgen will pay nearly $125 million to resolve claims they used charities that help cover Medicare patients’ out-of-pocket drug costs as a way to pay kickbacks aimed at encouraging the use of their high-priced medications.
Novartis Poaches GSK Veteran as New Sandoz CEO
GlaxoSmithKline veteran Richard Saynor is coming home to Sandoz after being named the new chief executive officer of the Novartis subsidiary.
Novartis shares rise after lifting 2019 profit outlook
Novartis raised the company’s 2019 profit target, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval in May 2019.
UK-Based Accelerator Start Codon Launches with Investment from Genentech and Others
Start Codon launched in Cambridge, England with funding from keystone investors including Cambridge Innovation Capital, Babraham Bioscience Technologies, Genentech, Jonathan Milner and Ian Tomlinson.
Eli Lilly Sells Two Legacy Drugs and Manufacturing Facility for $375 Million
Lilly inked a deal with Eddingpharm for the rights to two legacy antibiotic medicines and a manufacturing facility in Suzhou, China.
Nocion Therapeutics Launches With $27 Million to Focus on Chronic Cough and Pain
Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.
Talaris Rebrands With New Leadership Team
Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.
Arrakis to Create New Class of rSM Oncology Drugs
With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.
Gilead teams up with insitro for experimental NASH treatments
Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.
Ad Right Top
Most Commented
Sorry. No data so far.
MedAdNews
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com. 
April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!